Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ImmunoGen, Inc. IMGN
$13.39
-$0.09 (-0.70%)
На 18:00, 12 мая 2023
-51.98%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3036120100.00000000
-
week52high
14.00
-
week52low
3.10
-
Revenue
108782000
-
P/E TTM
-14
-
Beta
0.93598600
-
EPS
-0.89000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 июл 2023 г. в 12:30
Описание компании
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 06 мая 2022 г. |
| RBC Capital | Sector Perform | Outperform | 21 мар 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 22 февр 2022 г. |
| BMO Capital | Outperform | 11 февр 2022 г. | |
| Jefferies | Buy | Hold | 01 дек 2021 г. |
| Barclays | Overweight | 09 сент 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 16 ноя 2022 г. |
| Canaccord Genuity | Buy | Buy | 16 ноя 2022 г. |
| BMO Capital | Outperform | Outperform | 16 ноя 2022 г. |
| Barclays | Overweight | Overweight | 15 ноя 2022 г. |
| Truist Securities | Buy | 21 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 30 дек 2022 г. |
| JP Morgan | Neutral | Neutral | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McCain Tracey L | A | 50303 | 2772 | 30 дек 2022 г. |
| MITCHELL DEAN J | A | 142667 | 3024 | 30 дек 2022 г. |
| Goldberg Mark Alan | A | 160350 | 3402 | 30 дек 2022 г. |
| Berkenblit Anna | A | 110671 | 436 | 30 дек 2022 г. |
| Wingrove Theresa | A | 83345 | 1131 | 30 дек 2022 г. |
| Lentini Renee | A | 19648 | 1351 | 30 дек 2022 г. |
| VASCONCELLES MICHAEL | A | 960000 | 960000 | 29 дек 2022 г. |
| Lentini Renee | A | 37500 | 37500 | 22 дек 2022 г. |
| Char Daniel | A | 400000 | 400000 | 30 ноя 2022 г. |
| Harrington-Smith Kristen | D | 50000 | 25000 | 15 ноя 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | 2540851 | 929775 | 30 сент 2022 г. |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2075700 | 672900 | 31 дек 2021 г. |
| SPDR S&P Biotech ETF | 5877860 | -302477 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 4925380 | 0 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 3665950 | 105032 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 1792740 | -2524 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 2521660 | -12942 | 31 июл 2020 г. |
| Fidelity Select Biotechnology Portfolio | 1573740 | 0 | 31 июл 2020 г. |
| Vanguard Explorer Fund | 8133130 | -188640 | 30 июн 2020 г. |
| Vanguard Strategic Equity Fund | 3091560 | -237010 | 30 июн 2020 г. |
Новостная лента
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
MarketBeat
08 мая 2023 г. в 08:31
Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progression-free survival (PFS) and overall survival (OS) for patients in a MIRASOL late-stage study.
ImmunoGen stock price doubles after ovarian cancer candidate Elahere aces phase 3 study
Proactive Investors
03 мая 2023 г. в 12:36
ImmunoGen Inc stock more than doubled after the company shared positive topline data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and effectiveness of its experimental ovarian cancer drug Elahere. The study compared Elahere with chemo in patients with platinum-resistant ovarian cancer, who have received one to three prior lines of therapy.
Why ImmunoGen Stock Is Soaring Wednesday
The Motley Fool
03 мая 2023 г. в 11:53
The company said it anticipates asking for full approval of Elahere from the FDA. The drug was granted accelerated approval in November to treat advanced ovarian cancer.
Wall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
Zacks Investment Research
03 мая 2023 г. в 11:26
The mean of analysts' price targets for ImmunoGen (IMGN) points to a 101.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Is ImmunoGen (IMGN) Stock Up 125% Today?
InvestorPlace
03 мая 2023 г. в 10:04
ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a Phase 3 trial for treating ovarian cancer. According to a press release, the company reported positive top-line data from its clinical trial of Elahere.